ID   POL_HV1LW               Reviewed;        1435 AA.
AC   P0C6F2;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   18-MAR-2008, sequence version 1.
DT   24-JUN-2015, entry version 63.
DE   RecName: Full=Gag-Pol polyprotein;
DE   AltName: Full=Pr160Gag-Pol;
DE   Contains:
DE     RecName: Full=Matrix protein p17;
DE              Short=MA;
DE   Contains:
DE     RecName: Full=Capsid protein p24;
DE              Short=CA;
DE   Contains:
DE     RecName: Full=Spacer peptide 1 {ECO:0000250|UniProtKB:P12497};
DE              Short=SP1;
DE     AltName: Full=p2;
DE   Contains:
DE     RecName: Full=Nucleocapsid protein p7;
DE              Short=NC;
DE   Contains:
DE     RecName: Full=Transframe peptide;
DE              Short=TF;
DE   Contains:
DE     RecName: Full=p6-pol;
DE              Short=p6*;
DE   Contains:
DE     RecName: Full=Protease;
DE              EC=3.4.23.16;
DE     AltName: Full=PR;
DE     AltName: Full=Retropepsin;
DE   Contains:
DE     RecName: Full=Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.1.26.13;
DE     AltName: Full=Exoribonuclease H;
DE              EC=3.1.13.2;
DE     AltName: Full=p66 RT;
DE   Contains:
DE     RecName: Full=p51 RT;
DE   Contains:
DE     RecName: Full=p15;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
GN   Name=gag-pol;
OS   Human immunodeficiency virus type 1 group M subtype B (isolate LW123)
OS   (HIV-1).
OC   Viruses; Retro-transcribing viruses; Retroviridae; Orthoretrovirinae;
OC   Lentivirus; Primate lentivirus group.
OX   NCBI_TaxID=82834;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=7826699;
RA   Reitz M.S. Jr., Hall L., Robert-Guroff M., Lautenberger J.A.,
RA   Hahn B.M., Shaw G.M., Kong L.I., Weiss S.H., Waters D., Gallo R.C.,
RA   Blattner W.;
RT   "Viral variability and serum antibody response in a laboratory worker
RT   infected with HIV type 1 (HTLV type IIIB).";
RL   AIDS Res. Hum. Retroviruses 10:1143-1155(1994).
RN   [2] {ECO:0000244|PDB:3LP3}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 1014-1149 IN COMPLEX WITH
RP   MANGANESE.
RX   PubMed=20484498; DOI=10.1128/JVI.00353-10;
RA   Su H.P., Yan Y., Prasad G.S., Smith R.F., Daniels C.L.,
RA   Abeywickrema P.D., Reid J.C., Loughran H.M., Kornienko M., Sharma S.,
RA   Grobler J.A., Xu B., Sardana V., Allison T.J., Williams P.D.,
RA   Darke P.L., Hazuda D.J., Munshi S.;
RT   "Structural basis for the inhibition of RNase H activity of HIV-1
RT   reverse transcriptase by RNase H active site-directed inhibitors.";
RL   J. Virol. 84:7625-7633(2010).
RN   [3] {ECO:0000244|PDB:3TH9}
RP   X-RAY CRYSTALLOGRAPHY (1.34 ANGSTROMS) OF 489-587.
RX   PubMed=21916489; DOI=10.1021/jm200778q;
RA   Ganguly A.K., Alluri S.S., Caroccia D., Biswas D., Wang C.H., Kang E.,
RA   Zhang Y., McPhail A.T., Carroll S.S., Burlein C., Munshi V., Orth P.,
RA   Strickland C.;
RT   "Design, synthesis, and X-ray crystallographic analysis of a novel
RT   class of HIV-1 protease inhibitors.";
RL   J. Med. Chem. 54:7176-7183(2011).
CC   -!- FUNCTION: Gag-Pol polyprotein: Mediates, with Gag polyrotein, the
CC       essential events in virion assembly, including binding the plasma
CC       membrane, making the protein-protein interactions necessary to
CC       create spherical particles, recruiting the viral Env proteins, and
CC       packaging the genomic RNA via direct interactions with the RNA
CC       packaging sequence (Psi). Gag-Pol polyprotein may regulate its own
CC       translation, by the binding genomic RNA in the 5'-UTR. At low
CC       concentration, the polyprotein would promote translation, whereas
CC       at high concentration, the polyprotein would encapsidate genomic
CC       RNA and then shutt off translation. {ECO:0000250}.
CC   -!- FUNCTION: Matrix protein p17: Targets the polyprotein to the
CC       plasma membrane via a multipartite membrane-binding signal, that
CC       includes its myristoylated N-terminus. Matrix protein is part of
CC       the pre-integration complex. Implicated in the release from host
CC       cell mediated by Vpu. Binds to RNA.
CC       {ECO:0000250|UniProtKB:P12497}.
CC   -!- FUNCTION: Capsid protein p24: Forms the conical core that
CC       encapsulates the genomic RNA-nucleocapsid complex in the virion.
CC       Most core are conical, with only 7% tubular. The core is
CC       constituted by capsid protein hexamer subunits. The core is
CC       disassembled soon after virion entry (By similarity). Host
CC       restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral
CC       capsids and cause premature capsid disassembly, leading to blocks
CC       in reverse transcription. Capsid restriction by TRIM5 is one of
CC       the factors which restricts HIV-1 to the human species. Host PIN1
CC       apparently facilitates the virion uncoating. On the other hand,
CC       interactions with PDZD8 or CYPA stabilize the capsid.
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000250|UniProtKB:P12497}.
CC   -!- FUNCTION: Nucleocapsid protein p7: Encapsulates and protects viral
CC       dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its
CC       zinc fingers. Acts as a nucleic acid chaperone which is involved
CC       in rearangement of nucleic acid secondary structure during gRNA
CC       retrotranscription. Also facilitates template switch leading to
CC       recombination. As part of the polyprotein, participates to gRNA
CC       dimerization, packaging, tRNA incorporation and virion assembly.
CC       {ECO:0000250|UniProtKB:P04585}.
CC   -!- FUNCTION: Protease: Aspartyl protease that mediates proteolytic
CC       cleavages of Gag and Gag-Pol polyproteins during or shortly after
CC       the release of the virion from the plasma membrane. Cleavages take
CC       place as an ordered, step-wise cascade to yield mature proteins.
CC       This process is called maturation. Displays maximal activity
CC       during the budding process just prior to particle release from the
CC       cell. Also cleaves Nef and Vif, probably concomitantly with viral
CC       structural proteins on maturation of virus particles. Hydrolyzes
CC       host EIF4GI and PABP1 in order to shut off the capped cellular
CC       mRNA translation. The resulting inhibition of cellular protein
CC       synthesis serves to ensure maximal viral gene expression and to
CC       evade host immune response (By similarity).
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- FUNCTION: Reverse transcriptase/ribonuclease H: Multifunctional
CC       enzyme that converts the viral RNA genome into dsDNA in the
CC       cytoplasm, shortly after virus entry into the cell. This enzyme
CC       displays a DNA polymerase activity that can copy either DNA or RNA
CC       templates, and a ribonuclease H (RNase H) activity that cleaves
CC       the RNA strand of RNA-DNA heteroduplexes in a partially processive
CC       3' to 5' endonucleasic mode. Conversion of viral genomic RNA into
CC       dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-
CC       binding site (PBS) situated at the 5'-end of the viral RNA. RT
CC       uses the 3' end of the tRNA primer to perform a short round of
CC       RNA-dependent minus-strand DNA synthesis. The reading proceeds
CC       through the U5 region and ends after the repeated (R) region which
CC       is present at both ends of viral RNA. The portion of the RNA-DNA
CC       heteroduplex is digested by the RNase H, resulting in a ssDNA
CC       product attached to the tRNA primer. This ssDNA/tRNA hybridizes
CC       with the identical R region situated at the 3' end of viral RNA.
CC       This template exchange, known as minus-strand DNA strong stop
CC       transfer, can be either intra- or intermolecular. RT uses the 3'
CC       end of this newly synthesized short ssDNA to perform the RNA-
CC       dependent minus-strand DNA synthesis of the whole template. RNase
CC       H digests the RNA template except for two polypurine tracts (PPTs)
CC       situated at the 5'-end and near the center of the genome. It is
CC       not clear if both polymerase and RNase H activities are
CC       simultaneous. RNase H probably can proceed both in a polymerase-
CC       dependent (RNA cut into small fragments by the same RT performing
CC       DNA synthesis) and a polymerase-independent mode (cleavage of
CC       remaining RNA fragments by free RTs). Secondly, RT performs DNA-
CC       directed plus-strand DNA synthesis using the PPTs that have not
CC       been removed by RNase H as primers. PPTs and tRNA primers are then
CC       removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to
CC       form a circular dsDNA intermediate. Strand displacement synthesis
CC       by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA
CC       copy of the viral genome that includes long terminal repeats
CC       (LTRs) at both ends. {ECO:0000250|UniProtKB:P04585}.
CC   -!- FUNCTION: Integrase: Catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry
CC       into a cell and reverse transcription of the RNA genome in dsDNA.
CC       The first step in the integration process is 3' processing. This
CC       step requires a complex comprising the viral genome, matrix
CC       protein, Vpr and integrase. This complex is called the pre-
CC       integration complex (PIC). The integrase protein removes 2
CC       nucleotides from each 3' end of the viral DNA, leaving recessed CA
CC       OH's at the 3' ends. In the second step, the PIC enters cell
CC       nucleus. This process is mediated through integrase and Vpr
CC       proteins, and allows the virus to infect a non dividing cell. This
CC       ability to enter the nucleus is specific of lentiviruses, other
CC       retroviruses cannot and rely on cell division to access cell
CC       chromosomes. In the third step, termed strand transfer, the
CC       integrase protein joins the previously processed 3' ends to the 5'
CC       ends of strands of target cellular DNA at the site of integration.
CC       The 5'-ends are produced by integrase-catalyzed staggered cuts, 5
CC       bp apart. A Y-shaped, gapped, recombination intermediate results,
CC       with the 5'-ends of the viral DNA strands and the 3' ends of
CC       target DNA strands remaining unjoined, flanking a gap of 5 bp. The
CC       last step is viral DNA integration into host chromosome. This
CC       involves host DNA repair synthesis in which the 5 bp gaps between
CC       the unjoined strands are filled in and then ligated. Since this
CC       process occurs at both cuts flanking the HIV genome, a 5 bp
CC       duplication of host DNA is produced at the ends of HIV-1
CC       integration. Alternatively, Integrase may catalyze the excision of
CC       viral DNA just after strand transfer, this is termed
CC       disintegration. {ECO:0000250|UniProtKB:P04585}.
CC   -!- CATALYTIC ACTIVITY: Specific for a P1 residue that is hydrophobic,
CC       and P1' variable, but often Pro. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- CATALYTIC ACTIVITY: Endohydrolysis of RNA in RNA/DNA hybrids.
CC       Three different cleavage modes: 1. sequence-specific internal
CC       cleavage of RNA. Human immunodeficiency virus type 1 and Moloney
CC       murine leukemia virus enzymes prefer to cleave the RNA strand one
CC       nucleotide away from the RNA-DNA junction. 2. RNA 5'-end directed
CC       cleavage 13-19 nucleotides from the RNA end. 3. DNA 3'-end
CC       directed cleavage 15-20 nucleotides away from the primer terminus.
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: 3'-end directed exonucleolytic cleavage of
CC       viral RNA-DNA hybrid. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at
CC       least 1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Protease: The viral protease is inhibited by
CC       many synthetic protease inhibitors (PIs), such as amprenavir,
CC       atazanavir, indinavir, loprinavir, nelfinavir, ritonavir and
CC       saquinavir. Use of protease inhibitors in tritherapy regimens
CC       permit more ambitious therapeutic strategies. Reverse
CC       transcriptase/ribonuclease H: RT can be inhibited either by
CC       nucleoside RT inhibitors (NRTIs) or by non nucleoside RT
CC       inhibitors (NNRTIs). NRTIs act as chain terminators, whereas
CC       NNRTIs inhibit DNA polymerization by binding a small hydrophobic
CC       pocket near the RT active site and inducing an allosteric change
CC       in this region. Classical NRTIs are abacavir, adefovir (PMEA),
CC       didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir
CC       (PMPA), zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs
CC       are atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266),
CC       emivirine (I-EBU), and nevirapine (BI-RG-587). The tritherapies
CC       used as a basic effective treatment of AIDS associate two NRTIs
CC       and one NNRTI. {ECO:0000250}.
CC   -!- SUBUNIT: Matrix protein p17: Homotrimer; further assembles as
CC       hexamers of trimers (By similarity). Matrix protein p17: Interacts
CC       with gp41 (via C-terminus) (By similarity). Matrix protein p17:
CC       interacts with host CALM1; this interaction induces a
CC       conformational change in the Matrix protein, triggering exposure
CC       of the myristate group (By similarity). Matrix protein p17:
CC       interacts with host AP3D1; this interaction allows the polyprotein
CC       trafficking to multivesicular bodies during virus assembly (By
CC       similarity). Matrix protein p17: Part of the pre-integration
CC       complex (PIC) which is composed of viral genome, matrix protein,
CC       Vpr and integrase (By similarity). Capsid protein p24: Homodimer;
CC       the homodimer further multimerizes as homohexamers or
CC       homopentamers. Capsid protein p24: Interacts with human PPIA/CYPA
CC       (By similarity); This interaction stabilizes the capsid. Capsid
CC       protein p24: Interacts with human NUP153 (By similarity). Capsid
CC       protein p24: Interacts with host PDZD8; this interaction
CC       stabilizes the capsid (By similarity). Capsid protein p24:
CC       Interacts with monkey TRIM5; this interaction destabilizes the
CC       capsid (By similarity).Protease: Homodimer, whose active site
CC       consists of two apposed aspartic acid residues. Reverse
CC       transcriptase/ribonuclease H: Heterodimer of p66 RT and p51 RT (RT
CC       p66/p51). Heterodimerization of RT is essential for DNA polymerase
CC       activity. Despite the sequence identities, p66 RT and p51 RT have
CC       distinct folding. Integrase: Homodimer; possibly can form
CC       homotetramer. Integrase: Part of the pre-integration complex (PIC)
CC       which is composed of viral genome, matrix protein, Vpr and
CC       integrase. Integrase: Interacts with human SMARCB1/INI1 and human
CC       PSIP1/LEDGF isoform 1. Integrase: Interacts with human KPNA3; this
CC       interaction might play a role in nuclear import of the pre-
CC       integration complex (By similarity). Integrase: Interacts with
CC       human NUP153; this interaction might play a role in nuclear import
CC       of the pre-integration complex (By similarity).
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000250|UniProtKB:P12497}.
CC   -!- SUBCELLULAR LOCATION: Gag-Pol polyprotein: Host cell membrane;
CC       Lipid-anchor. Host endosome, host multivesicular body. Note=These
CC       locations are linked to virus assembly sites. The main location is
CC       the cell membrane, but under some circumstances, late endosomal
CC       compartments can serve as productive sites for virion assembly.
CC       {ECO:0000250|UniProtKB:P12497}.
CC   -!- SUBCELLULAR LOCATION: Matrix protein p17: Virion membrane; Lipid-
CC       anchor {ECO:0000305}. Host nucleus {ECO:0000250}. Host cytoplasm
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Capsid protein p24: Virion {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Nucleocapsid protein p7: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Reverse transcriptase/ribonuclease H: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Integrase: Virion {ECO:0000305}. Host
CC       nucleus {ECO:0000305}. Host cytoplasm {ECO:0000305}. Note=Nuclear
CC       at initial phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Translation results in the formation of the Gag
CC         polyprotein most of the time. Ribosomal frameshifting at the
CC         gag-pol genes boundary occurs at low frequency and produces the
CC         Gag-Pol polyprotein. This strategy of translation probably
CC         allows the virus to modulate the quantity of each viral protein.
CC         Maintenance of a correct Gag to Gag-Pol ratio is essential for
CC         RNA dimerization and viral infectivity.;
CC       Name=Gag-Pol polyprotein;
CC         IsoId=P0C6F2-1; Sequence=Displayed;
CC         Note=Produced by -1 ribosomal frameshifting.;
CC       Name=Gag polyprotein;
CC         IsoId=Q70622-1; Sequence=External;
CC         Note=Produced by conventional translation.;
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: RT is structured in
CC       five subdomains: finger, palm, thumb, connection and RNase H.
CC       Within the palm subdomain, the 'primer grip' region is thought to
CC       be involved in the positioning of the primer terminus for
CC       accommodating the incoming nucleotide. The RNase H domain
CC       stabilizes the association of RT with primer-template.
CC       {ECO:0000250}.
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: The tryptophan
CC       repeat motif is involved in RT p66/p51 dimerization (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: Integrase: The core domain contains the D-x(n)-D-x(35)-E
CC       motif, named for the phylogenetically conserved glutamic acid and
CC       aspartic acid residues and the invariant 35 amino acid spacing
CC       between the second and third acidic residues. Each acidic residue
CC       of the D,D(35)E motif is independently essential for the 3'-
CC       processing and strand transfer activities of purified integrase
CC       protein. {ECO:0000250}.
CC   -!- PTM: Gag-Pol polyprotein: Specific enzymatic cleavages by the
CC       viral protease yield mature proteins. The protease is released by
CC       autocatalytic cleavage. The polyprotein is cleaved during and
CC       after budding, this process is termed maturation. Proteolytic
CC       cleavage of p66 RT removes the RNase H domain to yield the p51 RT
CC       subunit. Nucleocapsid protein p7 might be further cleaved after
CC       virus entry. {ECO:0000250|UniProtKB:P04585, ECO:0000255|PROSITE-
CC       ProRule:PRU00405}.
CC   -!- PTM: Matrix protein p17: Tyrosine phosphorylated presumably in the
CC       virion by a host kinase. Phosphorylation is apparently not a major
CC       regulator of membrane association. {ECO:0000250|UniProtKB:P04585}.
CC   -!- PTM: Capsid protein p24: Phosphorylated possibly by host MAPK1;
CC       this phosphorylation is necessary for Pin1-mediated virion
CC       uncoating. {ECO:0000250|UniProtKB:P12493}.
CC   -!- PTM: Nucleocapsid protein p7: Methylated by host PRMT6, impairing
CC       its function by reducing RNA annealing and the initiation of
CC       reverse transcription. {ECO:0000250|UniProtKB:P03347}.
CC   -!- MISCELLANEOUS: Reverse transcriptase/ribonuclease H: Error-prone
CC       enzyme that lacks a proof-reading function. High mutations rate is
CC       a direct consequence of this characteristic. RT also displays
CC       frequent template switching leading to high recombination rate.
CC       Recombination mostly occurs between homologous regions of the two
CC       copackaged RNA genomes. If these two RNA molecules derive from
CC       different viral strains, reverse transcription will give rise to
CC       highly recombinated proviral DNAs. {ECO:0000250}.
CC   -!- MISCELLANEOUS: HIV-1 lineages are divided in three main groups, M
CC       (for Major), O (for Outlier), and N (for New, or Non-M, Non-O).
CC       The vast majority of strains found worldwide belong to the group
CC       M. Group O seems to be endemic to and largely confined to Cameroon
CC       and neighboring countries in West Central Africa, where these
CC       viruses represent a small minority of HIV-1 strains. The group N
CC       is represented by a limited number of isolates from Cameroonian
CC       persons. The group M is further subdivided in 9 clades or subtypes
CC       (A to D, F to H, J and K).
CC   -!- MISCELLANEOUS: Resistance to inhibitors associated with mutations
CC       are observed both in viral protease and in reverse transcriptase.
CC       Most of the time, single mutations confer only a modest reduction
CC       in drug susceptibility. Combination of several mutations is
CC       usually required to develop a high-level drug resistance. These
CC       mutations are predominantly found in clade B viruses and not in
CC       other genotypes. They are listed in the clade B representative
CC       isolate HXB2 (AC P04585).
CC   -!- SIMILARITY: Contains 2 CCHC-type zinc fingers.
CC       {ECO:0000255|PROSITE-ProRule:PRU00047}.
CC   -!- SIMILARITY: Contains 1 integrase catalytic domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00457}.
CC   -!- SIMILARITY: Contains 1 integrase-type DNA-binding domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00506}.
CC   -!- SIMILARITY: Contains 1 integrase-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00450}.
CC   -!- SIMILARITY: Contains 1 peptidase A2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- SIMILARITY: Contains 1 reverse transcriptase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- SIMILARITY: Contains 1 RNase H domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00408}.
CC   -!- WEB RESOURCE: Name=HIV drug resistance mutations;
CC       URL="https://www.iasusa.org/content/hiv-drug-resistance-mutations";
CC   -!- WEB RESOURCE: Name=hivdb; Note=HIV drug resistance database;
CC       URL="http://hivdb.stanford.edu";
CC   -!- WEB RESOURCE: Name=BioAfrica: HIV bioinformatics in Africa;
CC       URL="http://www.bioafrica.net/index.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U12055; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 3LP3; X-ray; 2.80 A; A/B=1014-1149.
DR   PDB; 3TH9; X-ray; 1.34 A; A/B=489-587.
DR   PDB; 3VFA; X-ray; 1.43 A; A/B=489-587.
DR   PDB; 4I8W; X-ray; 1.96 A; A/B=489-587.
DR   PDB; 4I8Z; X-ray; 1.75 A; A/B=489-587.
DR   PDB; 4MC1; X-ray; 1.39 A; A/B=489-587.
DR   PDB; 4MC2; X-ray; 1.56 A; A/B=489-587.
DR   PDB; 4MC6; X-ray; 1.31 A; A/B=489-587.
DR   PDB; 4MC9; X-ray; 1.19 A; A/B=489-587.
DR   PDB; 4NYF; X-ray; 1.90 A; A/B=1199-1357.
DR   PDB; 4QGI; X-ray; 1.90 A; A/B=489-587.
DR   PDBsum; 3LP3; -.
DR   PDBsum; 3TH9; -.
DR   PDBsum; 3VFA; -.
DR   PDBsum; 4I8W; -.
DR   PDBsum; 4I8Z; -.
DR   PDBsum; 4MC1; -.
DR   PDBsum; 4MC2; -.
DR   PDBsum; 4MC6; -.
DR   PDBsum; 4MC9; -.
DR   PDBsum; 4NYF; -.
DR   PDBsum; 4QGI; -.
DR   ProteinModelPortal; P0C6F2; -.
DR   SMR; P0C6F2; 2-432, 489-1143, 1148-1417.
DR   EvolutionaryTrace; P0C6F2; -.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0072494; C:host multivesicular body; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004533; F:exoribonuclease H activity; IEA:UniProtKB-EC.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0015074; P:DNA integration; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; IEA:UniProtKB-KW.
DR   GO; GO:0039651; P:induction by virus of host cysteine-type endopeptidase activity involved in apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:suppression by virus of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0046718; P:viral entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   GO; GO:0019076; P:viral release from host cell; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.200; -; 1.
DR   Gene3D; 1.10.1200.30; -; 1.
DR   Gene3D; 1.10.150.90; -; 1.
DR   Gene3D; 1.10.375.10; -; 1.
DR   Gene3D; 2.30.30.10; -; 1.
DR   Gene3D; 2.40.70.10; -; 1.
DR   Gene3D; 3.30.420.10; -; 2.
DR   Gene3D; 4.10.60.10; -; 1.
DR   InterPro; IPR001969; Aspartic_peptidase_AS.
DR   InterPro; IPR000721; Gag_p24.
DR   InterPro; IPR001037; Integrase_C_retrovir.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR017856; Integrase_Zn-bd_dom-like_N.
DR   InterPro; IPR003308; Integrase_Zn-bd_dom_N.
DR   InterPro; IPR000071; Lentvrl_matrix_N.
DR   InterPro; IPR012344; Matrix_HIV/RSV.
DR   InterPro; IPR018061; Pept_A2A_retrovirus_sg.
DR   InterPro; IPR001995; Peptidase_A2_cat.
DR   InterPro; IPR021109; Peptidase_aspartic_dom.
DR   InterPro; IPR008916; Retrov_capsid_C.
DR   InterPro; IPR008919; Retrov_capsid_N.
DR   InterPro; IPR010999; Retrovr_matrix.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR010659; RVT_connect.
DR   InterPro; IPR010661; RVT_thumb.
DR   InterPro; IPR001878; Znf_CCHC.
DR   Pfam; PF00540; Gag_p17; 1.
DR   Pfam; PF00607; Gag_p24; 1.
DR   Pfam; PF00552; IN_DBD_C; 1.
DR   Pfam; PF02022; Integrase_Zn; 1.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00077; RVP; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF06815; RVT_connect; 1.
DR   Pfam; PF06817; RVT_thumb; 1.
DR   Pfam; PF00098; zf-CCHC; 2.
DR   PRINTS; PR00234; HIV1MATRIX.
DR   SMART; SM00343; ZnF_C2HC; 2.
DR   SUPFAM; SSF46919; SSF46919; 1.
DR   SUPFAM; SSF47353; SSF47353; 1.
DR   SUPFAM; SSF47836; SSF47836; 1.
DR   SUPFAM; SSF47943; SSF47943; 1.
DR   SUPFAM; SSF50122; SSF50122; 1.
DR   SUPFAM; SSF50630; SSF50630; 1.
DR   SUPFAM; SSF53098; SSF53098; 2.
DR   SUPFAM; SSF57756; SSF57756; 1.
DR   PROSITE; PS50175; ASP_PROT_RETROV; 1.
DR   PROSITE; PS00141; ASP_PROTEASE; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS51027; INTEGRASE_DBD; 1.
DR   PROSITE; PS50879; RNASE_H; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   PROSITE; PS50158; ZF_CCHC; 2.
DR   PROSITE; PS50876; ZF_INTEGRASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host caspases by virus; AIDS;
KW   Aspartyl protease; Capsid protein; DNA integration; DNA recombination;
KW   DNA-binding; DNA-directed DNA polymerase; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cell membrane;
KW   Host cytoplasm; Host endosome; Host gene expression shutoff by virus;
KW   Host membrane; Host nucleus; Host-virus interaction; Hydrolase;
KW   Lipid-binding; Lipoprotein; Magnesium; Membrane; Metal-binding;
KW   Modulation of host cell apoptosis by virus; Multifunctional enzyme;
KW   Myristate; Nuclease; Nucleotidyltransferase; Phosphoprotein; Protease;
KW   Repeat; Ribosomal frameshifting; RNA-binding;
KW   RNA-directed DNA polymerase; Transferase; Viral genome integration;
KW   Viral nucleoprotein; Viral penetration into host nucleus; Virion;
KW   Virion maturation; Virus entry into host cell;
KW   Virus exit from host cell; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed; by host. {ECO:0000250}.
FT   CHAIN         2   1435       Gag-Pol polyprotein. {ECO:0000250}.
FT                                /FTId=PRO_0000325028.
FT   CHAIN         2    132       Matrix protein p17. {ECO:0000250}.
FT                                /FTId=PRO_0000325029.
FT   CHAIN       133    363       Capsid protein p24. {ECO:0000250}.
FT                                /FTId=PRO_0000325030.
FT   PEPTIDE     364    377       Spacer peptide 1. {ECO:0000250}.
FT                                /FTId=PRO_0000325031.
FT   CHAIN       378    432       Nucleocapsid protein p7. {ECO:0000250}.
FT                                /FTId=PRO_0000325032.
FT   PEPTIDE     433    440       Transframe peptide. {ECO:0000255}.
FT                                /FTId=PRO_0000325033.
FT   CHAIN       441    488       p6-pol. {ECO:0000255}.
FT                                /FTId=PRO_0000325034.
FT   CHAIN       489    587       Protease. {ECO:0000250}.
FT                                /FTId=PRO_0000325035.
FT   CHAIN       588   1147       Reverse transcriptase/ribonuclease H.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000325036.
FT   CHAIN       588   1027       p51 RT. {ECO:0000250}.
FT                                /FTId=PRO_0000325037.
FT   CHAIN      1028   1147       p15. {ECO:0000250}.
FT                                /FTId=PRO_0000325038.
FT   CHAIN      1148   1435       Integrase. {ECO:0000250}.
FT                                /FTId=PRO_0000325039.
FT   DOMAIN      508    577       Peptidase A2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00275}.
FT   DOMAIN      631    821       Reverse transcriptase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   DOMAIN     1021   1144       RNase H. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00408}.
FT   DOMAIN     1201   1351       Integrase catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00457}.
FT   ZN_FING     390    407       CCHC-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING     411    428       CCHC-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING    1150   1191       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00450}.
FT   DNA_BIND   1370   1417       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00506}.
FT   REGION        7     31       Interaction with Gp41.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION        8     43       Interaction with host CALM1.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION       12     19       Interaction with host AP3D1.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION       14     33       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate and
FT                                RNA. {ECO:0000250|UniProtKB:P12497}.
FT   REGION       73     77       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION      189    227       Interaction with human PPIA/CYPA and
FT                                NUP153. {ECO:0000250|UniProtKB:P12497}.
FT   REGION      277    363       Dimerization/Multimerization of capsid
FT                                protein p24.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      489    493       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      537    543       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      576    588       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      814    822       RT 'primer grip'. {ECO:0000250}.
FT   MOTIF        16     22       Nuclear export signal. {ECO:0000250}.
FT   MOTIF        26     32       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       985   1001       Tryptophan repeat motif. {ECO:0000250}.
FT   COMPBIAS    688    691       Poly-Lys.
FT   ACT_SITE    513    513       For protease activity; shared with
FT                                dimeric partner. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10094}.
FT   METAL       697    697       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       772    772       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       773    773       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL      1030   1030       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305|PubMed:20484498}.
FT   METAL      1065   1065       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305|PubMed:20484498}.
FT   METAL      1085   1085       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305|PubMed:20484498}.
FT   METAL      1136   1136       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL      1211   1211       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL      1263   1263       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL      1299   1299       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250|UniProtKB:P04585}.
FT   SITE        132    133       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        221    222       Cis/trans isomerization of proline
FT                                peptide bond; by human PPIA/CYPA.
FT                                {ECO:0000250}.
FT   SITE        363    364       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        377    378       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        432    433       Cleavage; by viral protease.
FT                                {ECO:0000255}.
FT   SITE        440    441       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        488    489       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        587    588       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        988    988       Essential for RT p66/p51
FT                                heterodimerization. {ECO:0000250}.
FT   SITE       1001   1001       Essential for RT p66/p51
FT                                heterodimerization. {ECO:0000250}.
FT   SITE       1027   1028       Cleavage; by viral protease; partial.
FT                                {ECO:0000255}.
FT   SITE       1147   1148       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   MOD_RES     132    132       Phosphotyrosine; by host. {ECO:0000250}.
FT   LIPID         2      2       N-myristoyl glycine; by host.
FT                                {ECO:0000250}.
FT   STRAND      493    495       {ECO:0000244|PDB:4MC9}.
FT   STRAND      498    503       {ECO:0000244|PDB:4MC9}.
FT   STRAND      506    512       {ECO:0000244|PDB:4MC9}.
FT   STRAND      517    521       {ECO:0000244|PDB:4MC1}.
FT   STRAND      530    537       {ECO:0000244|PDB:4MC9}.
FT   STRAND      540    554       {ECO:0000244|PDB:4MC9}.
FT   STRAND      557    566       {ECO:0000244|PDB:4MC9}.
FT   HELIX       575    578       {ECO:0000244|PDB:4MC9}.
FT   TURN        579    582       {ECO:0000244|PDB:4MC9}.
FT   STRAND      584    586       {ECO:0000244|PDB:4MC9}.
FT   STRAND     1025   1033       {ECO:0000244|PDB:3LP3}.
FT   TURN       1035   1037       {ECO:0000244|PDB:3LP3}.
FT   STRAND     1040   1046       {ECO:0000244|PDB:3LP3}.
FT   STRAND     1051   1058       {ECO:0000244|PDB:3LP3}.
FT   HELIX      1061   1074       {ECO:0000244|PDB:3LP3}.
FT   STRAND     1078   1084       {ECO:0000244|PDB:3LP3}.
FT   HELIX      1087   1094       {ECO:0000244|PDB:3LP3}.
FT   HELIX      1103   1113       {ECO:0000244|PDB:3LP3}.
FT   STRAND     1116   1122       {ECO:0000244|PDB:3LP3}.
FT   HELIX      1130   1140       {ECO:0000244|PDB:3LP3}.
FT   STRAND     1207   1215       {ECO:0000244|PDB:4NYF}.
FT   STRAND     1218   1225       {ECO:0000244|PDB:4NYF}.
FT   TURN       1226   1228       {ECO:0000244|PDB:4NYF}.
FT   STRAND     1231   1239       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1241   1254       {ECO:0000244|PDB:4NYF}.
FT   STRAND     1259   1261       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1266   1268       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1271   1280       {ECO:0000244|PDB:4NYF}.
FT   STRAND     1283   1286       {ECO:0000244|PDB:4NYF}.
FT   TURN       1293   1295       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1296   1312       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1313   1315       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1319   1332       {ECO:0000244|PDB:4NYF}.
FT   HELIX      1343   1355       {ECO:0000244|PDB:4NYF}.
SQ   SEQUENCE   1435 AA;  162076 MW;  36226C1CBDB26464 CRC64;
     MGARASVLSG GKLDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL LETSEGCRQI
     LGQLQPSLQT GSEECRSLYN TVATLYCVHQ RIEIKDTKEA LDKIKEEQNK SKKKAQQAAA
     DTGHSSQVSQ NYPIVQNIQG QMVHQAISPR TLNAWVKVVE EKAFSPEVIP MFSALSEGAT
     PQDLNTMLNT VGGHQAAMQM LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT
     STLQEQIGWM TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF
     YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC QGVGGPGHKA
     RVLAEAMSQV TNSATIMMQR GNFRNQRKIV KCFNCGKEGH IARNCRAPRK KGCWKCGKEG
     HQMKDCTERQ ANFFREDLAF LQGKAREFSS EQTRANSPTR RELQVWGRDN NSPSEAGADR
     QGTVSFNFPQ ITLWQRPLVT IKIGGQLKEA LLDTGADDTV LEEMSLPGRW KPKMIGGIGG
     FIKVRQYDQI LIEICGHKAI GTVLVGPTPV NIIGRNLLTQ IGCTLNFPIS PIETVPVKLK
     PGMDGPKVKQ WPLTEEKIKA LVEICTEMEK EGKISKIGPE NPYNTPVFAI KKKDSTKWRK
     LVDFRELNKR TQDFWEVQLG IPHPAGLKKK KSVTVLDVGD AYFSVPLDED FRKYTAFTIP
     SINNETPGIR YQYNVLPQGW KGSPAIFQSS MTKILEPFRK QNPDIVIYQY MDDLYVGSDL
     EIGQHRTKIE ELRQHLLRWG LTTPDKKHQK EPPFLWMGYE LHPDKWTVQP IVLPEKDSWT
     VNDIQKLVGK LNWASQIYPG IKVRQLCKLL RGTKALTEVI PLTEEAELEL AENREILKEP
     VHGVYYDPSK DLIAEIQKQG QGQWTYQIYQ EPFKNLKTGK YARMRGTHTN DVKQLTEAVQ
     KITTESIVIW GKTPKFKLPI QKETWETWWT EYWQATWIPE WEFVNTPPLV KLWYQLEKEP
     IVGAETFYVD GAANRETKLG KAGYVTNKGR QKVVPLTNTT NQKTELQAIY LALQDSGLEV
     NIVTDSQYAL GIIQAQPDKS ESELVNQIIE QLIKKEKVYL AWVPAHKGIG GNEQVDKLVS
     AGIRKILFLD GIDKAQDEHE KYHSNWRAMA SDFNLPPVVA KEIVASCDKC QLKGEAMHGQ
     VDCSPGIWQL DCTHLEGKVI LVAVHVASGY IEAEVIPAET GQETAYFLLK LAGRWPVKTI
     HTDNGSNFTS ATVKAACWWA GIKQEFGIPY NPQSQGVVES MNKELKKIIG QVRDQAEHLK
     TAVQMAVFIH NFKRKGGIGG YSAGERIVDI IATDIQTKEL QKQITKIQNF RVYYRDSRNP
     LWKGPAKLLW KGEGAVVIQD NSDIKVVPRR KAKIIRDYGK QMAGDDCVAS RQDED
//
